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Background
Some reports have shown that co-inheritance of α-thalassemia and sickle cell disease 
improves hematological parameters and results in a relatively mild clinical picture for 
patients; however, the exact molecular basis and clinical significance of the interaction 
between α-thalassemia and sickle cell disease in India has not yet been described. There 
is little agreement on the clinical effects of α-thalassemia on the phenotype of sickle cell 
disease.
Methods
Complete blood count and red cell indices were measured by an automated cell analyzer. 
Quantitative assessment of hemoglobin variants HbF, HbA, HbA2, and HbS was 
performed by high performance liquid chromatography (HPLC). DNA extraction was 
performed using the phenol-chloroform method, and molecular study for common 
α-deletions was done by gap-PCR.
Results
Out of 60 sickle cell anemia patients, the α-thalassemia genotype was found in 18 patients. 
Three patients had the triplicated α-genotype (Anti α-3.7 kb), and the remaining patients 
did not have α-deletions. This study indicates that patients with co-existing α-thalassemia 
and sickle cell disease had a mild phenotype, significantly improved hematological 
parameters, and fewer blood transfusions than the patients with sickle cell anemia without 
co-existing α-deletions.
Conclusion
Co-existence of α-thalassemia and sickle cell anemia has significant effects on the 
phenotype of Indian sickle cell patients.
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INTRODUCTION
The interaction of α-thalassemia with sickle cell anemia 
(hemoglobin SS disease, HbSS) is known to influence hemato-
logical indices, reduce hemolytic rate and intravascular sick-
ling, and increase deformation of the red blood cells. 
Decreased synthesis of the hemoglobin variant HbS is due 
to decreased availability of α chains to combine with β
s 
chains. α-thalassemia is a heterogeneous group of disorders 
that are characterized by impaired synthesis of α-globin 
chains because of deletions involving one or both of the 
α-globin genes. It is predicted that the lower concentration 
of HbS associated with α-thalassemias would mitigate the 
clinical severity of sickle cell disease.
α-thalassemia is the most common single gene disorder 
in the world. DNA analysis carried out in certain regions 
of India has shown that α3.7 and α4.2 are the most common 
single gene deletions [1]. Some larger deletions like 20.5 
kb, SA, and SEA have been reported in the Indian population. 
Eight α-chain deletions causing α-thalassemia (α
3.7, α
4.2, SEA, 
THAI, SA, 20.5 kb, MED, and FI) have been described. 
Hemoglobin Koya Dora is found at high frequency (10%) 
in certain communities of Andhra Pradesh [2]. The α
0 alleles 
are less common in India compared to neighboring Southeast 
Asian countries like China and Taiwan. α-thalassemia is 
highly prevalent in the tribal populations with a frequency 
o f  1 - 4 0 %  i n  A n d h r a  P r a d e s h  and Gujarat. The genotype Korean J Hematol 2011;46:192-5.
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Table 1. Comparative hematological parameters with and without 
the co-existence of α-thalassemia genotype in sickle cell anemia 
patients.
Parameter
Mean±SD
P
Sickle cell 
anemia with 
α deletion
(N=18)
 Sickle cell 
anemia 
without 
α deletion 
(N=42)
RBC (millions of cells/μL)
HGB (g/dL)
HCT (%)
MCV (fL)
MCH (pg)
MCHC (g/dL)
3.4±2.4
9.01±2.5
27.4±4.8
66.1±6.4
28.8±6.7
32.03±2.9
3.1±0.8
7.2±2.4
25.2±3.1
58.3±3.4
24.1±4.2
30.2±1.8
0.033
0.012
0.031
＜0.001
0.001
0.004
Table 2. Comparative clinical parameter with and without alpha 
thalassemia genotype in sickle cell anemia patients.
Clinical parameter
Frequency %
SS with 
alpha deletion
(N=18)
SS without 
alpha deletion
(N=42)
Anemia           50% 59.52%
Pallor 38.89% 45.23%
Weakness 33.34% 40.47%
Fever 27.78% 30.95%
Hepatomegaly 11.12% 23.07%
Splenomegaly 16.67% 19.04%
Painful crises 16.67% 21.42%
Gall stone 11.12% 16.66%
Chest pain 11.12% 16.66%
Jaundice 11.12% 16.66%
Hyper pigmentation 11.12% 14.28%
Avascular necrosis   5.56% 14.28%
Retinopathy None 7.69%
Septicemia None 5.12%
Deep vein thrombosis None 2.56%
Pulmonary embolism None 2.56%
Leg ulcer None 4.76%
Blood transfusion 27.78% 40.47%
of α-thalassemia that is prevalent in India is α+, which is 
clinically silent both in the heterozygous and homozygous 
states. Hence, it is free from morbidity [3].
A clinically important feature of α-thalassemia is its inter-
action with sickle cell disease. It has been shown that co-in-
heritance of α-thalassemia and sickle cell disease improves 
the hematological parameters of heterozygous β-thalassemia 
and results in a relatively mild clinical picture of homozygous 
β-thalassemia [4, 5]. The influence of α-thalassemia on the 
features of sickle cell disease has not been well characterized. 
The exact molecular basis of the interaction of α-thalassemia 
with sickle cell disease in India has not yet been described. 
The two most common forms of α-thalassemia are 3.7 and 
4.2 kb deletions; these forms are geographically widespread. 
α-thalassemia is found in a high proportion of a tribal pop-
ulation in south and east India, and a study indicated an 
estimated gene frequency of 0.32 among patients with sickle 
cell disease [6, 7]. A few studies state that sickle cell patients 
with α-thalassemia have higher total hemoglobin levels and 
changes that are compatible with slower hemolysis than 
patients with sickle cell anemia alone [8-10]. However the 
clinical significance of the interaction of α-thalassemia with 
sickle cell disease remains controversial. Thus, the objective 
of our study was to investigate the effect of α-thalassemia 
genotypes on clinical and hematological parameters in pa-
tients with sickle cell anemia.
MATERIALS AND METHODS
Subjects in this study included patients with sickle cell 
anemia who were recruited from the Hematology Outpatient 
Department at the All India Institute of Medical Sciences 
in New Delhi, India. This study was approved by the institu-
tional ethical committee. About 5 mL of venous blood was 
drawn after obtaining signed consent from the patient. DNA 
was extracted by the phenol-chloroform method. Complete 
blood count and red cell indices were measured by an auto-
mated cell analyzer (SYSMEX K-4500, Kobe, Japan). A cation 
exchange high performance liquid chromatography (HPLC- 
Bio-Rad-Variant
TM, Bio Rad, Hercules, CA, USA) was used 
for the quantitative assessment of hemoglobin variants HbA, 
HbF, HbA2, and HbS and the diagnosis of sickle cell anemia 
in patients. Identification of α-deletions and triplication was 
performed by gap-PCR. α-3.7 and α-4.2 kb deletions and 
triplication ααα (anti 3.7 kb) were identified using the meth-
ods described by Baysal and Huisman [11] and Smetanina 
and Huisman [12]. Identification of South African deletions 
was performed according to Shaji et al. [1], while Southeast 
Asian deletion was identified according to Chang et al. [13]. 
Mean values, standard deviations, and frequency dis-
tributions were used to evaluate the hematological and clin-
ical data. Student’s t-test was used to compare the means 
of groups using GraphPad software (version 3.06). P＜0.05 
was considered statistically significant.
RESULTS
Blood samples were collected and characterized from a 
total of 60 patients with sickle cell anemia. After identi-
fication of α mutations, subjects were categorized in 3 groups 
according to the α-thalassemia genotype. Eighteen patients, 
including 10 males and 8 females with a mean age of 10.4±6.7 
years, had α-deletions. Three patients, including 2 males 
and 1 female with a mean age of 18±6.1 years, had anti 
α-3.7 kb (α-triplication). The remaining 39 patients did not 
have an α-deletion, had a mean age of 11.41±8.1 years, and 
included 24 males and 16 females.
Patients with α-deletions had higher hemoglobin, mean 
corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH) levels, and mean corpuscular hemoglobin concen-
tration (MCHC) than patients without α-deletions. Mean Korean J Hematol 2011;46:192-5.
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differences of hematological variables among patients with 
α-deletions and patients without α-deletions were statisti-
cally significant. Details are provided in Table 1. Patients 
without  α-deletions had greater severity and higher fre-
quency of clinical manifestations. Comparative clinical fre-
quency details are given in Table 2.
Screening of single (α3.7 and α4.2 kb) deletions, double 
(--SA and --SEA) deletions, and α-triplication (anti 3.7 kb) 
was performed by gap-PCR in all subjects. The most frequent 
mutation in patients with sickle cell anemia was α-3.7 hetero-
zygous (50%), followed by α-3.7 homozygous (38.9%), and 
α-4.2 heterozygous (11.1%), while α-triplication was found 
in 3 (5%) patients. None of the patients had double (--SA 
and --SEA) deletions.
DISCUSSION
Most cases of α-thalassemia result from deletions that 
originate from unequal crossover events in the α-globin gene 
cluster (α-3.7 and α-4.2) and large deletions probably result-
ing from illegitimate recombination, while non-deletional 
forms are geographically more localized and less common 
[14, 15]. Higgs et al. [8] reported that homozygotes had 
significantly lower chronic leg ulceration and acute chest 
syndrome and a significantly greater persistence of splenome-
galy among Jamaican patients. Because of this finding, one 
might have expected that the hematologic effect of α-tha-
lassemia in Indians would be also reflected by a greater 
prevalence of splenomegaly in the α-thalassemia group. 
However, in Indians, splenomegaly was common and oc-
curred at a later age than in the Jamaican patients [6]; this 
was probably related to the raised HbF levels in Indian pa-
tients, and an additional effect of α-thalassemia on the rate 
of splenomegaly was not observed. This might suggest that 
the effect of α-thalassemia is not large enough to be notice-
able in a population with another strong genetic ameliorating 
factor like raised HbF levels [16].
Our cases of sickle cell anemia present only single α-chain 
deletions (α-3.7 and α-4.2 kb) and α-triplication. The α-4.2 
deletion was present only in the heterozygous state. Overall, 
30% of patients with sickle cell anemia had an α-thalassemia 
genotype. Patients with sickle cell anemia and homozygous 
α-deletion showed significant differences in hematological 
as well as clinical presentation. There is considerable evi-
dence that patients with sickle cell and α-thalassemia have 
increased prevalence of splenomegaly with episodes of splen-
ic sequestration, increased retinopathy, increased avascular 
necrosis, fewer leg ulcers, and fewer symptomatic cere-
bro-vascular accidents [8, 17-26]. The effect of α-thalassemia 
on the incidence of acute chest syndrome and acute painful 
episodes is controversial. Some investigators reported re-
duced incidence of acute chest syndrome [8, 24], but other 
studies refuted this finding [17, 27]. The effect of α-thalasse-
mia on the frequency of acute painful episodes is even more 
controversial. One group of investigators reported a de-
creased incidence of acute painful episodes in patients with 
sickle cell and α-thalassemia [28], Another group reported 
higher incidence of acute painful episodes [24, 29], and a 
third group found no difference in the frequency of acute 
painful episodes in the presence or absence of α-thalassemia 
[30]. We report a higher frequency of splenomegaly (19.0%), 
acute chest pain (16.7%), and painful crisis (21.4%) in patients 
with sickle cell anemia without co-existent α-deletions than 
patients with sickle cell anemia and α-thalassemia. This dis-
crepancy among reports may be due to several factors. One 
possibility is that subjects with α-thalassemia have higher 
hematocrit (HCT) readings and hence have increased blood 
viscosity that predisposes patients to vaso-occlusion and pain-
ful episodes. Along the same lines, increased blood viscosity 
predisposes patients to a higher incidence of another painful 
condition, avascular necrosis, which has been well docu-
mented [19, 20].
The cases of sickle cell homozygous patients with a co-ex-
isting α-deletion but without a characterized α-thalassemia 
genotype showed great variability in clinical and hemato-
logical parameters. Our sickle cell anemia patients without 
an  α-thalassemia genotype had lower mean hemoglobin, 
MCV, MCH, HCT, and MCHC, and these parameters were 
improved in patients with α-deletions. Red cell indices were 
statistically significant in an entire group of patients. Clinical 
symptoms occurred at higher frequency and were more se-
vere in patients without α-deletions compared to patients 
who had α-deletions. Due to the low number of α-triplicated 
patients, we did not evaluate these patients separately, and 
instead included them in the without α-deletion group of 
patients. We observed that sickle cell anemia patients with 
α-deletions presented milder symptoms, improved hemato-
logical parameters, and less dependency on blood transfusion 
than sickle cell anemia patients without α-deletions. This 
finding suggested that the presence of α-thalassemia geno-
types influenced clinical manifestations of Indian sickle cell 
anemia patients.
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